RHONE POULENC SANTE – Trademark Portfolio

Entity Type: 09

RHONE POULENC SANTE holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. The owner is based in COURBEVOIE.

LES MIROIRS, 18 AVENUE D'ALSACE

COURBEVOIE 92400 , FR

17 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IMOVANE
IMOVANE
Cancelled 1990
TAXOTERE
TAXOTERE
Cancelled 1990
TOPREK
TOPREK
Cancelled 1990
KETOFEN
KETOFEN
Cancelled 1989
SURIL
SURIL
Abandoned 1989
CLEXAN
CLEXAN
Abandoned 1988
RHODAPAP
RHODAPAP
Cancelled 1987
SECTRIDE
SECTRIDE
Cancelled 1986
ORUVAIL
ORUVAIL
Cancelled 1983
ORUDIS
ORUDIS
Cancelled 1983
PIPORTIL
PIPORTIL
Cancelled 1983
RHODINE
RHODINE
Cancelled 1982
EMTRYMIX
EMTRYMIX
Cancelled 1963

Trademark Classifications

RHONE POULENC SANTE's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (17 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does RHONE POULENC SANTE have?

RHONE POULENC SANTE has 17 U.S. trademarks filed with the USPTO.

What trademark classes does RHONE POULENC SANTE file in?

RHONE POULENC SANTE files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is RHONE POULENC SANTE's trademark registration success rate?

RHONE POULENC SANTE has a 0% trademark registration rate, with 0 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.